I wanted to give you an update on this point. Jerome is a scientific advisor for ExcisionBio, which means that ExcisionBio is well aware that Jerome is targeting the latent copies with meganucleases.
Also, in the lastest video, Jerome said that "The team is collaborating with others to pursue a CRISPR/Cas9-based solution, which would have some advantages over meganucleases, and they are exploring other delivery mechanisms such as nanoparticles. "
When he said so, very likely he meant ExcisionBio. So there is a mutual exchange and the target is the same.
Regarding the clinical trial in China: they made a new publication in which they show that they can target the latent copies:
“The therapy, which is dripped into patients' eyes, can find and 'cut' the virus hidden in the nervous system, which then degrades by itself," Cai said. "With this technology, we can cure keratitis and terminate the virus."
"HELP was capable of eliminating the viral reservoir via retrograde transport from corneas to trigeminal ganglia. "
They have already applied the therapy to 2 patients. Hopefully there will be soon an update from them:
“Clinical trials on two patients have also been carried out and the results are being evaluated,”
"you don’t need to keep making coronavirus protein forever in order to maintain the protective immunity"
it means: even if mRNA is gone and your body isn't producing the viral proteins anymore, the immune system will still maintain memory of how to produce the right antibodies against it.